Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 16/20 | 0.54 |
| ▸ | HSP90B1 | P14625 | 12/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872294 | 0.78 | TRAP1 (0.55) | TRAP1HSP90B1HSP90AA1ADORA2A | |
| SCHEMBL4551948 | 0.76 | ADORA2B (0.46) | TRAP1ADORA3ADORA2BADORA2A | |
| SCHEMBL17773077 | 0.75 | ALDH1A1 (0.38) | TRAP1HSP90B1ADORA3ADORA2BADORA2A | |
| SCHEMBL23629388 | 0.75 | TRAP1 (0.53) | TRAP1HSP90B1HSP90AA1ADORA2A | |
| SCHEMBL5173890 | 0.75 | TRAP1 (0.53) | TRAP1HSP90B1HSP90AA1ADORA2A | |
| SCHEMBL11215917 | 0.75 | PDE4A (0.43) | ADORA3ADORA2BADORA2A | |
| SCHEMBL8673254 | 0.74 | TRAP1 (0.52) | TRAP1HSP90B1HSP90AA1ADORA2A | |
| SCHEMBL30012102 | 0.70 | TRAP1 (0.69) | TRAP1HSP90B1HSP90AA1ADORA2A | |
| SCHEMBL23202316 | 0.70 | TRAP1 (0.69) | TRAP1HSP90B1HSP90AA1ADORA2A | |
| SCHEMBL18039294 | 0.69 | ADORA2B (0.40) | ADORA3ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2012791-A2 | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007092496-A2 | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | HSP90B1, HSP90AB2P, HSP90AB1 | TRAP1 14/4885HSP90B1 1/4885HSP90AA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.